In early December, the EU banned imports from a Ranbaxy facility that makes injectable antibiotics after the unit failed an inspection. The Dewas plant unit did not meet EU GMP standards, Ranbaxy said in a stock market filing on Thursday, while all other units at the facility were approved. All exports to the US from Ranbaxy remain barred. [For more on Ranbaxy’s compliance problems with FDA and on data integrity findings in India see IPQ April 28, 2014.]
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
